세계의 조직진단 시장(-2028년) : 제품(소모품(항체, 시약, 조직, 프로브), 장비(처리 시스템, 스캐너), 기술(ISH, IHC, 슬라이드 염색), 질병 유형(유방암, 림프종, 전립선암)별
Tissue Diagnostics Market by Product (Consumables (Antibodies, Reagents, Tissue, Probes ), Instrument (Processing System, Scanner)), Technology (ISH, IHC, Slide Staining), Disease Type (Breast Cancer, Lymphoma, Prostate Cancer) - Global Forecast to 2028
상품코드:1409025
리서치사:MarketsandMarkets
발행일:2024년 01월
페이지 정보:영문 254 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
보고서 개요
조사 범위
조사 대상년도
2021-2028년
기준년도
2022년
예측 기간
2023-2028년
단위
금액(USD)
부문
제품, 기술, 질환 유형, 최종사용자, 지역
대상 지역
북미, 유럽, 아시아태평양, 기타
세계 조직진단 시장 규모는 2023년 56억 달러에서 예측 기간 동안 8.4%의 연평균 복합 성장률(CAGR)을 나타내고, 2028년에는 84억 달러에 달할 것으로 예상됩니다.
제품별로는 소모품 부문이 2022년 가장 큰 비중을 차지할 것으로 예상됩니다. 생명과학 및 암 연구에 대한 정부 및 민간의 자금 투입 증가, 대형 제약사의 R&D 비용 증가 등의 요인이 이 부문의 성장에 기여하고 있습니다. 또한, 효과적인 결과와 정확한 진단을 제공하는 우수한 소모품의 가용성 또한 수요 증가로 이어져 이 부문의 성장을 견인하고 있습니다.
기술별로는 면역조직화학(IHC) 부문이 2022년 가장 큰 점유율을 차지할 것으로 추정됩니다. 고령 인구 증가, 암 질환의 유병률 증가, 당뇨병, IHC 검사에 대한 보험 적용 가능성, 디지털 파소로지 도입 등의 요인이 IHC 제품 수요를 견인하고 있습니다.
질병별로는 유방암 부문이 2022년 가장 큰 점유율을 차지할 것으로 보입니다. 이는 연령, 가족력, 생식력, 높은 유선 조직 밀도, 운동 부족, 음주, 흡연, 방사선 노출 등의 요인에 더해 비침윤성 유관암(DCIS), 침윤성 유관암(IDC), 염증성 유방암(IBC)과 같은 유방암의 발생률이 증가하고 있기 때문입니다.
지역별로는 아시아태평양이 예측 기간 동안 가장 높은 성장률을 보일 것으로 예상됩니다. 아시아태평양의 높은 성장세는 많은 인구, 아시아 지역의 경제 성장, 아시아 국가들의 암 유병률 증가에 기인합니다.
세계의 조직진단 시장을 조사했으며, 시장 개요, 시장 영향요인 분석, 기술 및 특허 동향, 규제 환경, 시장 규모 추이 및 예측, 각 부문별/지역별 상세 분석, 경쟁 구도, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 프리미엄 인사이트
제5장 시장 개요
시장 역학
성장 촉진요인
성장 억제요인
기회
과제
업계 동향
밸류체인 분석
공급망 분석
기술 분석
Porter의 Five Forces 분석
주요 이해관계자와 구입 기준
규제 상황
특허 분석
주요 컨퍼런스 및 이벤트
가격 분석
무역 분석
에코시스템 시장/맵
고객 사업에 영향을 미치는 동향/파괴적 변화
제6장 조직진단 시장 : 제품별
소모품
항체
키트
시약
프로브
기기
슬라이드 염색 시스템
스캐너
조직 처리 시스템
기타
제7장 조직진단 시장 : 기술별
면역조직화학
IN SITU HYBRIDIZATION
디지털 병리학 및 워크플로우 관리
특수 염색
제8장 조직진단 시장 : 질환 유형별
유방암
위암
림프종
전립선암
비소세포폐암
기타
제9장 조직진단 시장 : 최종사용자별
병원
연구기관
제약회사
CRO
기타
제10장 조직진단 시장 : 지역별
북미
유럽
아시아태평양
기타 지역
제11장 경쟁 구도
개요
주요 기업의 전략
주요 기업의 매출 분석
시장 점유율 분석
기업 평가 매트릭스
신규 기업/중소기업 평가 매트릭스
신규 기업/중소기업 경쟁 벤치마킹
경쟁 시나리오와 동향
제12장 기업 개요
주요 기업
F. HOFFMANN-LA ROCHE LTD.
DANAHER CORPORATION
PHC HOLDINGS CORPORATION
THERMO FISHER SCIENTIFIC INC.
ABBOTT
AGILENT TECHNOLOGIES, INC.
MERCK KGAA
SAKURA FINETEK JAPAN CO., LTD.
ABCAM PLC
BECTON, DICKINSON AND COMPANY(BD)
BIO SB
BIOGENEX
CELL SIGNALING TECHNOLOGY, INC.
HISTO-LINE LABORATORIES
SLEE MEDICAL GMBH
CELLPATH LTD.
기타 기업
AMOS SCIENTIFIC PTY LTD.
JINHUA YIDI MEDICAL APPLIANCE CO., LTD.
MEDITE MEDICAL GMBH
DIAPATH S.P.A.
KFBIO KONFOONG BIOINFORMATION TECH CO., LTD
DIAGNOSTIC BIOSYSTEMS INC.
3DHISTECH LTD.
RWD LIFE SCIENCE CO., LTD.
DAKEWE
SYSMEX CORPORATION
ENZO LIFE SCIENCES, INC.
BIOCARE MEDICAL, LLC.
MILESTONE MEDICAL
BIO-OPTICA MILANO SPA
제13장 부록
LSH
영문 목차
영문목차
Report Description
Scope of the Report
Years Considered for the Study
2021-2028
Base Year
2022
Forecast Period
2023-2028
Units Considered
Value (USD) Billion
Segments
Product, Technology, Disease Type, End User, and Region
Regions covered
North America, Europe, APAC, and Rest of the World
The global tissue diagnostics market is projected to reach USD 8.4 billion by 2028 from USD 5.6 billion in 2023, at a CAGR of 8.4% during the forecast period. Market growth is driven by factors such as the rising prevalence of cancer, increasing availability of reimbursements and increasing technological advancements in tissue diagnostics are the major factors driving the growth of the market.
"The Consumables to register the largest share of the tissue diagnostics market, by product."
The global tissue diagnostics market product segment is divided into Consumables and Instruments . In product segment the consumables is expected to account for the largest share of the tissue diagnostics market in 2022. Market growth is largely driven by the rise in government and private funding in life sciences and cancer research, growing R&D expenditure by leading pharma companies. Moreover, the availability of better consumables that offer efficient results and precision in diagnosis attributes to their growing demand, resulting in growth of the segment.
"Immunohistochemistry tissue diagnostics segment to grow at a considerable rate among technology during the forecast period."
The tissue diagnostics market is four technology segments, namely, Immunohistochemistry (IHC), In Situ Hybridization (ISH), Digital Pathology & Workflow, and Special Staining. The Immunohistochemistry technology segment is expected to account for the largest share of the tissue diagnostics market in 2022. The large share of this segment can primarily be attributed to the Rising geriatric population and growing prevalence of cancer diseases diabetes, availability of reimbursements for IHC tests, and adoption of digital pathology are driving the demand for immunohistochemistry products.
"Breast Cancer segment accounted for the largest share in the tissue diagnostics market, by disease."
The global tissue diagnostics market is segmented into Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non-small Cell Lung Cancer, and Other Diseases. The breast cancer segment accounted for a largest share in 2022, primarily due number of factors such as age, family history, reproductive history, the presence of dense breast tissues, a lack of physical activity, alcohol consumption, smoking, radiation exposure coupled with the increasing incidence of breast cancer such as ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and inflammatory breast cancer (IBC), among others.
"Asia Pacific: The fastest-growing region in the tissue diagnostics market."
The global tissue diagnostics market is segmented into four major regions - North America, Europe, the Asia Pacific, and Rest of the World (RoW). The Asia Pacific region is expected to grow at the highest rate in the tissue diagnostics market during the forecast period. The high growth in the region is due to the presence of a large target population, the economic growth in the countries of this region and rising prevalence of cancer in Asian countries.
The break-up of the profile of primary participants in the tissue diagnostics market:
By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
By Designation: C-level - 27%, D-level - 18%, and Others - 55%
By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, and Rest of the World- 10%
The key players in this market are F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), PHC Holdings Corporation Corporation (Japan), Agilent Technologies Inc. (US), Thermo Fisher Scientific, Inc (US), Abbott (US), Merck KGAA (Germany), SAKURA FINETEK JAPAN CO., LTD (Japan), Abcam Plc. (UK), Becton, Dickinson and Company (BD) (US), Bio SB (US), Biogenix (US), Cell Signaling Technology, Inc (US), Histo-Line Laboratories (Italy), SLEE Medical GMBH (Germany), Cellpath Ltd (UK), Amos scientific Pty Ltd. (Australia), Jinhua YIDI Medical Appliance CO.,LTD (China), MEDITE Medical GmbH (Germany), Diapath S.p.A. (Italy), KONFOONG BIOINFORMATION TECH CO.,LTD (China), Diagnostic BioSystems Inc. (US), 3DHISTECH (Hungary), RWD Life Science Co.,LTD (China), Dakewei Biotechnology co., Ltd (China), Sysmax Corporation (Japan), Enzo Life Sciences, Inc. (US), Biocare Medical, LLC. (US), MILESTONE MEDICAL (US), and Bio-Optica Milano Spa (Italy).
Research Coverage:
This research report categorizes the tissue diagnostics market by product (consumables and instruments), technology (immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology & workflow management, special staining), disease type (breast cancer, gastric cancer, lymphoma, prostate cancer, non-small cell lung cancer, other disease types), end user (hospitals, research laboratories, pharmaceutical companies, Contract Research Organizations (CROs), and Other End Users), and region (North America, Europe, Asia Pacific, and Rest of the World). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the tissue diangostics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products offered, key strategies, acquisitions, and partnerships. New product launches and approvals, and recent developments associated with the tissue diagnostics market. This report covers the competitive analysis of upcoming startups in the tissue diangostics market ecosystem.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall tissue diagnostics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
Analysis of key drivers (the rising prevalence of cancer, growing healthcare expenditure, growing demand for digital pathology, increasing healthcare expenditure, developing infrastructure for cancer diagnosis, increasing availability of reimbursements, and increasing technological advancements in tissue diagnostics are the major factors driving the growth of the market), restraints (high degree of consolidation, high cost of diagnostic imaging system), opportunities (significant opportunities in BRICS countries, growing demand for personalized medicines, increasing number of clinical trails perraining to cancer drugs, emerging economics to offer significant opportunities to companies), challenges (lack of skilled professionals, availability of refurbished products, stringent regulatory requirements, lack of infrastructure and low awareness in middle and low income countries and lack of standardization ) and trends (Increasing number of reagent rental agreements, increasing usage of Al in histopathology ) influencing the growth of the tissue diagnostics market
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the tissue diagnostics market.
Market Development: Comprehensive information about lucrative markets - the report analyses the tissue diagnostics market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the tissue diagnostics market
Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Agilent Technologies (US), Thermo Fisher Scientific Inc. (US), and among others in the tissue diagnostics market strategies.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS AND EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 MARKETS COVERED
FIGURE 1 MARKET SEGMENTATION
1.4.2 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY RESEARCH
2.1.2.1 Primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 16 CHINA & INDIA TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD
4.4 TISSUE DIAGNOSTICS MARKET: REGIONAL MIX
FIGURE 17 ASIA PACIFIC REGION IS PROJECTED TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
4.5 TISSUE DIAGNOSTICS MARKET: DEVELOPED COUNTRIES VS. EMERGING ECONOMIES
FIGURE 18 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 TISSUE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising incidence of cancer and infectious diseases
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2018 VS. 2020 VS. 2040
5.2.1.2 Growing demand for digital pathology
5.2.1.3 Increasing healthcare expenditure
FIGURE 20 CURRENT HEALTH EXPENDITURE PER CAPITA
FIGURE 21 CURRENT HEALTH EXPENDITURE (% OF GDP)
5.2.1.4 Growing availability of reimbursements
5.2.1.5 Rising establishment of private diagnostics centers
5.2.2 RESTRAINTS
5.2.2.1 High cost of tissue diagnostic systems
5.2.2.2 Stringent regulatory requirements
5.2.3 OPPORTUNITIES
5.2.3.1 High growth potential of emerging economies
FIGURE 22 GROWTH IN CURRENT HEALTHCARE EXPENDITURE IN BRICS COUNTRIES, 2012-2020
5.2.3.2 Growing preference for personalized medicines
FIGURE 23 PERSONALIZED MEDICINES APPROVED BY FDA (%), 2015-2022
5.2.3.3 Increasing number of clinical trials for cancer therapeutics
5.2.4 CHALLENGES
5.2.4.1 Shortage of skilled professionals
5.2.4.2 Availability of refurbished products
5.2.4.3 Inadequate standardization for TDx
5.2.5 INDUSTRY TRENDS
5.2.5.1 Increasing number of reagent rental agreements
5.2.5.2 Growing usage of AI in histopathology
5.3 VALUE CHAIN ANALYSIS
FIGURE 24 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 25 DIRECT DISTRIBUTION-PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.5 TECHNOLOGY ANALYSIS
5.6 PORTER'S FIVE FORCES ANALYSIS
5.6.1 THREAT OF NEW ENTRANTS
5.6.2 BARGAINING POWER OF BUYERS
5.6.3 BARGAINING POWER OF SUPPLIERS
5.6.4 THREAT OF SUBSTITUTES
5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 KEY STAKEHOLDERS AND BUYING CRITERIA
5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USERS
TABLE 4 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%)
5.7.2 BUYING CRITERIA
FIGURE 27 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 5 KEY BUYING CRITERIA FOR END USERS
5.8 REGULATORY LANDSCAPE
TABLE 6 INDICATIVE LIST OF REGULATORY AUTHORITIES IN TISSUE DIAGNOSTICS MARKET
5.9 PATENT ANALYSIS
5.10 KEY CONFERENCES AND EVENTS
TABLE 7 LIST OF CONFERENCES & EVENTS (2023-2024)
5.11 PRICING ANALYSIS
TABLE 8 PRICE RANGE FOR TISSUE DIAGNOSTICS
5.12 TRADE ANALYSIS
TABLE 9 IMPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL/CHEMICAL ANALYSIS, BY COUNTRY, 2018-2022 (USD MILLION)
TABLE 10 EXPORT DATA FOR MICROTOMES, PARTS, AND ACCESSORIES OF INSTRUMENTS AND APPARATUS FOR PHYSICAL/CHEMICAL ANALYSIS, BY COUNTRY, 2018-2022 (USD MILLION)
5.13 ECOSYSTEM MARKET/MAP
TABLE 11 TISSUE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
FIGURE 28 KEY PLAYERS OPERATING IN TISSUE DIAGNOSTICS MARKET
*Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.
